scholarly journals Molecular Pathology of Hepatic Neoplasms: Classification and Clinical Significance

2011 ◽  
Vol 2011 ◽  
pp. 1-15 ◽  
Author(s):  
Zenta Walther ◽  
Dhanpat Jain

Recent technological advances have enabled investigators to characterize the molecular genetics and genomics of hepatic neoplasia in remarkable detail. From these studies, an increasing number of molecular markers are being identified that correlate with clinically important tumor phenotypes. This paper discusses current knowledge relevant to the molecular classification of epithelial primary hepatic tumors that arise in adults, including focal nodular hyperplasia (FNH), hepatocellular adenoma (HCA), hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC. Genetic analysis has defined molecular subtypes of HCA that are clinicopathologically distinct and can be distinguished through immunohistochemistry. Gene expression studies have identified molecular signatures of progression from dysplastic nodules (DNs) to early HCC in cirrhosis. Analyses of the mutational spectra, chromosomal aberrations and instability, transcriptomics, and microRNA profiles of HCC have revealed the existence of biologically distinct subtypes of this common malignancy, with prognostic implications. Molecular characterization of biliary and hepatic progenitor cell phenotypes in liver cancer has shed new light on the histogenesis of these tumors and has focused attention on novel therapeutic targets. In coming years, the molecular classification of hepatic neoplasms will be increasingly valuable for guiding patient care, as targeted therapies for liver cancer are developed and brought into clinical practice.

2019 ◽  
Vol 23 (2) ◽  
pp. 109
Author(s):  
Xue-Yin Shen ◽  
Xu-Guang Hu ◽  
Young-Bae Kim ◽  
Mi-Na Kim ◽  
Sung-Yeon Hong ◽  
...  

2004 ◽  
Vol 10 (9) ◽  
pp. 2922-2927 ◽  
Author(s):  
Giovanni Parmigiani ◽  
Elizabeth S. Garrett-Mayer ◽  
Ramaswamy Anbazhagan ◽  
Edward Gabrielson

2017 ◽  
Vol 67 (5) ◽  
pp. 1074-1083 ◽  
Author(s):  
Jean-Charles Nault ◽  
Valérie Paradis ◽  
Daniel Cherqui ◽  
Valérie Vilgrain ◽  
Jessica Zucman-Rossi

2017 ◽  
Vol 152 (4) ◽  
pp. 880-894.e6 ◽  
Author(s):  
Jean-Charles Nault ◽  
Gabrielle Couchy ◽  
Charles Balabaud ◽  
Guillaume Morcrette ◽  
Stefano Caruso ◽  
...  

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Mei-Mei Li ◽  
Jun Yuan ◽  
Xin-Yuan Guan ◽  
Ning-Fang Ma ◽  
Ming Liu

AbstractHuman gastrointestinal malignancies are highly heterogeneous cancers. Clinically, heterogeneity largely contributes to tumor progression and resistance to therapy. Heterogeneity within gastrointestinal cancers is defined by molecular subtypes in genomic and transcriptomic analyses. Cancer stem cells (CSCs) have been demonstrated to be a major source of tumor heterogeneity; therefore, assessing tumor heterogeneity by CSC trait-guided classification of gastrointestinal cancers is essential for the development of effective therapies. CSCs share critical features with embryonic stem cells (ESCs). Molecular investigations have revealed that embryonic genes and developmental signaling pathways regulating the properties of ESCs or cell lineage differentiation are abnormally active and might be oncofetal drivers in certain tumor subtypes. Currently, multiple strategies allow comprehensive identification of tumor subtype-specific oncofetal signatures and evaluation of subtype-specific therapies. In this review, we summarize current knowledge concerning the molecular classification of gastrointestinal malignancies based on CSC features and elucidate their clinical relevance. We also outline strategies for molecular subtype identification and subtype-based therapies. Finally, we explore how clinical implementation of tumor classification by CSC subtype might facilitate the development of more effective personalized therapies for gastrointestinal cancers.


2014 ◽  
Vol 44 (2) ◽  
pp. 119-124
Author(s):  
TaoTao HU ◽  
ZeGuang HAN

2021 ◽  
Vol 86 (4) ◽  
pp. 258-262
Author(s):  
Jiří Presl ◽  
◽  
Tomáš Vaněček ◽  
Michael Michal ◽  
Jiří Bouda ◽  
...  

Summary: Objective: The main objective of the article is to clearly inform healthcare professionals about the newly implemented molecular classification of endometrial cancer into practice. Methods: Summary of current knowledge, recommendations and new procedures relating to molecular genetic examination of the tissues of patients with endometrial carcinoma. Results: Endometrial cancer is currently diagnosed on the base of histopathological morphology. According to the classical Bokhman division, we distinguish between two relatively wide groups of tumors which are different in pathogenesis: type I – estrogen-dependent tumors, clinically usually indolent, and type II – non-endometroid tumors, clinically aggressive, without dependence on estrogen stimulation. This classification fulfills a  didactic purpose and provides easy orientation for epidemiological data, but is not suitable for stratification due to the overlap of clinical, pathological and molecular features. The Cancer Genome Atlas project classifies endometrial tumors into 4  groups based on molecular genetic features. Conclusion: Integration of the histopathological findings along with molecular classification appears to be the best approach for evaluating each individual tumor. This will help to achieve the ideal stratifi cation of patients for treatment regimens.


Author(s):  
Antonio Pico ◽  
Laura Sanchez-Tejada ◽  
Ruth Sanchez-Ortiga ◽  
Rosa Camara ◽  
Cristina Lamas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document